Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in extending overall survival when combined with AstraZeneca’s Faslodex (fulvestrant) in the treatment of breast cancer.
The study of 669 participants from which the data was drawn focused on the efficacy of the drug combo in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer previously treated with endocrine therapy.
